SELLAS Life Sciences Group, Inc.
NASDAQ:SLS · NASDAQ Capital Market
+$0.31 today
Vol 14.69M · Avg 7.79M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+370.76%
Period High
$9.31
Period Low
$1.39
Latest
$8.05
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$332.97M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$330.88M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$260.10M
OmniAb, Inc.
NASDAQ:OABI
$252.47M
Codexis, Inc.
NASDAQ:CDXS
$220.43M
Protara Therapeutics, Inc.
NASDAQ:TARA
$155.32M
MediWound Ltd.
NASDAQ:MDWD
$153.22M
Invivyd, Inc.
NASDAQ:IVVD
$130.22M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$96.78M
What is the latest SLS filing?
The latest filing shown is S-8 dated Jun 16, 2026.
How many recent filings does SLS have?
Intrinsic Alpha currently shows 20 recent filings for SLS.
Explore More
Continue the stock analysis
Jump to another research area for this company.